A SPANISH firm is set to step up its search for a cure for Alzheimer’s after reporting positive results from clinical trials.
Pharmaceutical company Zeltia gave Alzheimer’s patients an oral dose of a drug known as Tideglusib on a daily basis over a 26-week period.
The Madrid-based firm found the drug significantly reduced the build-up of so-called ‘plaques and tangles’ on the brain, which are thought to play a key role in the development of the disease.
It also reported improved ‘spatial memory’, the part of the brain that records information about your surroundings.
The trial involved 306 Alzheimer’s patients at 55 hospitals in Spain, the UK, France, Finland and Germany.
There is currently no known cure for Alzheimer’s disease, a form of dementia characterised by memory loss.
Dementia affects 820,000 people in the UK, according to Alzheimer’s Research UK.